Eroxon (MED3000) / Futura Medical - LARVOL DELTA

Fluorescence sensor enabled control of contaminants of emerging concern in reclaimed wastewater using ozone-based treatment processes. (PubMed, Water Res) - "Furthermore, real-time fluorescence data were successfully used to predict observed pseudo-first-order rate constants of CEC with O3 or O3/H2O2. Obtained results suggest that real-time fluorescence monitoring is an excellent tool to control CEC removal during O3-based AOPs and monitor the transferred ozone in wastewater (R2≥0.94), contributing to the optimization of reagent dose, energy and costs."

Journal

The role of TiO2 and gC3N4 bimetallic catalysts in boosting antibiotic resistance gene removal through photocatalyst assisted peroxone process. (PubMed, Sci Rep) - "Furthermore, Polymerase Chain Reaction-Denaturing Gradient Gel Electrophoresis (PCR-DGGE) analysis reveals challenges in eradicating GC-rich bacteria with TiO2 and g-C3N4 processes, while slight differences in Cu/Pd loadings suggest g-C3N4-based ozonation improved antibacterial effectiveness. Terminal Restriction Fragment Length Polymorphism analysis highlights the efficacy of the photocatalyst-assisted peroxone process in treating diverse samples."

Journal

Using green nanocomposite containing eggshell in the electroperoxone process in a baffled reactor to remove the emerging tetracycline pollutant. (PubMed, Environ Res) - "Additionally, the reusability of the nanocomposite was evaluated over five usage periods, during which the process efficiency decreased from 95.9% to 83.1%. In short, this study proved that EMAC/Fe3O4 nanocomposites are promising electroperoxone catalysts due to their low cost, excellent stability and reusability, environmental compatibility, and superior catalytic activity for TCH antibiotics removal."

Journal

Scoping review exploring advancements in topical agent therapies for erectile dysfunction. (PubMed, Sex Med Rev) - "Topical agents via various mechanisms are effective and well-tolerated treatments for ED. A fast-acting drug that significantly reduces side effects as compared with other options has been discovered. However, its efficacy relative to current first-line therapies remains unclear. Topical agents present a viable therapeutic alternative for individuals who are unable or unwilling to take oral phosphodiesterase 5 inhibitors."

Journal • Review • Erectile Dysfunction

Formation of chlorinated disinfection byproducts in textile industry waste water: Emerging concerns and current issues (ACS-Fall 2024) - "Study findings revealed that conventionally treated effluents contained higher levels of DBPs, emphasizing the need for more eco-friendly treatment approaches. The application of electroperoxone not only demonstrated superior color removal but also offered a more environmentally responsible solution for the textile industry."

Defluorination of PFOA in trickle bed electrochemical reactor with intensified absorption of bubble (ACS-Fall 2024) - "Subsequently, ●OH generated via peroxon reaction (of O3 and H2O2) can further oxidize the mono-defluorination intermediates...This trickle bed enhanced with electrochemical processes provides a new approach for effective PFOA degradation and defluorination in drinking water. experimental setup"

Balancing organic pollutant removal and bromate formation during peroxone treatment of bromide containing waters (ACS-Fall 2024) - "The influence of O3(g) interphase mass transfer rate and mixing within the reactor on the overall performance of the process will also be discussed. Simulation of reactor performance using modelling tools such as computation fluid dynamics incorporating both multiphase flow and reactions kinetics describing ozone decay, hydroxyl radical generation and organic oxidation will also be presented."

E-peroxone with a novel GDE decorated with hydrophobic membrane for the degradation of pyridine: Stability, byproducts and toxicity. (PubMed, Chemosphere) - "The toxicity variation along the degradation progress was evaluated with microbial respiration tests and Toxicity Estimation Software Tool (T.E.S.T.) calculation and an efficient detoxification capacity of E-peroxone was observed. This research provides a theoretical basis and technical support for the development of highly efficient and stable E-peroxone system for the elimination of toxic organic contaminants."

Journal

High-efficiently utilizing micro-nano ozone bubbles to enhance electro-peroxone process for rapid removal of trace pharmaceutical contaminants from hospital wastewater. (PubMed, Water Res) - "Consequently, the EP process under MNBs aeration significantly enhanced ozone-resistant ibuprofen (IBU) removal, achieving a removal rate of 98.4 ± 1.5 %, far exceeding the 47.3 ± 4.7 % observed with conventional aeration...As a result, over 97 % removal efficiency was achieved for five representative pharmaceutical pollutants (sulfamethoxazole, ribavirin, norfloxacin, tetracycline and ampicillin) in just 1 min. Furthermore, when applied to real hospital wastewater, the MNBs-O3-E treatment system reduced all 15 detected trace pharmaceutical compounds to below 10 ng L-1 and achieved 14 types of pollutants with removal rates of over 85 % within 15 min, resulting in an ultrahigh total removal rate of 98.6 %, from an initial total concentration of 2108 ng L-1 to less than 30 ng L-1. Thus, micro-nano aeration endowed the EP process as a promising advanced oxidation system for rapid and highly-effective removal of trace pharmaceutical contaminants from hospital..."

Journal

Ozone and peroxone disinfection of Toxocara canis eggs in water. (PubMed, Trop Biomed) - "The synergistic effect of ozone combined with hydrogen peroxide allows higher helminth egg inactivation rates, demonstrating that advanced oxidation processes are a real alternative to apply in the inactivation of Toxocara canis eggs. The results obtained in this study show that the ozone and peroxone treatment could be a useful disinfection process to destroy or inactivate Toxocara canis eggs in processes commonly applied in water treatment."

Journal

Efficacy and safety of MED3000, a novel topical therapy for the treatment of erectile dysfunction (AUA 2024) - "In a second multi-center, randomized, open-label, parallel-group study (FM71), MED3000 was compared with 5 mg oral tadalafil over 24 weeks in 96 men with ED. The data from these pivotal studies resulted in the approval of MED3000 in the United States. MED3000 met the MCID for improving erectile function with a favorable safety profile. This novel topical agent may be useful for men with ED who are not candidates for a PDE5 inhibitor, who cannot tolerate adverse events associated with these agents, or who have suboptimal responses to them."

Clinical • Erectile Dysfunction

Simultaneous electrocoagulation and E-peroxone coupled with ultrafiltration membrane for shale gas produced water treatment. (PubMed, Chemosphere) - "Mechanism study indicated that ECP could realize the simultaneous coagulation, H2O2 generation and activation by O3, facilitating the enhancement of ·OH and Alb production and therefore beneficial for improved water quality and UF fouling mitigation. Therefore, the ECP-UF process emerges as a highly efficient and space-saving approach, yielding a synergistic effect in mitigating UF fouling for SGPW recycling."

Journal

Insight into roles of carbon anodes for removal of refractory organic contaminants in electro-peroxone system: Mechanism, performance and stability. (PubMed, J Hazard Mater) - "In this work, the EP system with graphite felt anode (EP-GF) and activated carbon fiber anode (EP-ACF) was developed to enhance ibuprofen (IBP) removal. The three degradation pathways of IBP were proposed, and the toxicity of intermediates were evaluated. In general, carbon anodes have a good application prospect in the removal of ROCs in EP systems."

Journal

Crystal Plane Regulation Promotes the Oriented Conversion of Radicals in Heterogeneous Persulfate Catalyzed Oxidation Process. (PubMed, Small) - "The presence of Ov not only facilitates the adsorption of PMS molecules but also enhances electron transfer from Co2+ to PMS, leading to directed formation and efficient transformation of radicals. This study presents a novel strategy for promoting efficient radical formation in persulfate-activated systems."

Heterogeneity • Journal

Kinetic modelling assisted balancing of organic pollutant removal and bromate formation during peroxone treatment of bromide-containing waters. (PubMed, J Hazard Mater) - "For pollutants with low reactivity towards O3/•OH, high O3 (O3:DOC>>1 g/g) and high H2O2 dosages (O3:H2O2 ∼1 (g/g)) are required for minimizing BrO3- formation along with effective pollutant removal which may result in a very high residual of H2O2 in the effluent, causing secondary pollution. On balance, we conclude that the peroxone process is not effective for the removal of low reactivity micropollutants if minimization of BrO3- formation is also required."

Journal

Comparative study of different ultrasound based hybrid oxidation approaches for treatment of real effluent from coke oven plant. (PubMed, J Environ Manage) - "High-resolution liquid chromatography mass spectrometry (HR-LCMS) analysis was also performed to establish intermediate compounds. Overall, the coupling of ultrasound with oxidation processes produced better results with US + Peroxone established as best treatment approach for coke plant effluent."

Journal

Electric field-enhanced heterogeneous catalytic ozonation (EHCO) process for sulfadiazine removal: The role of cathodic reduction. (PubMed, Chemosphere) - "Further study proved that HO formed by O electrochemical reduction, peroxone reaction and electrochemical reduction of ozone contributed to improving ·OH generation. In addition, the EHCO system could achieve more than 80% SDZ removal within 2 min in different water matrices. These results confirmed that the EHCO process has a wide application perspective for refractory organics removal in actual wastewater."

Heterogeneity • Journal

Degradation of atrazine by electro-peroxone enhanced by Fe and N co-doped carbon nanotubes with simultaneous catalysis of HO and O. (PubMed, Chemosphere) - "Besides, Fe-N-CNT showed high catalytic activity and good stability during six cycles. This work provides an efficient activator for enhanced EP process, exhibiting a promising prospect for water and wastewater purification."

Journal

A comparative study of response surface methodology and artificial neural network based algorithm genetic for modeling and optimization of EP/US/GAC oxidation process in dexamethasone degradation: Application for real wastewater, electrical energy consumption. (PubMed, Chemosphere) - "This work deals with the study of integrated electro-peroxone/granular activated carbon (EP/US/GAC) process in the degradation of dexamethasone (DXM) from a water environment and the remediation of real pharmaceutical wastewater. The performance stability of EP/US/GAC system showed no remarkable drop in removal efficiency, and leakage of lead ions from the anode surface was negligible and below WHO guideline for drinking water. Generally, this research work manifested that the integrated EP/US/GAC system elevated the degradation efficiency and can be proposed as a pretreatment step before biological treatment processes for the remediation of recalcitrant wastewaters."

Journal

Nanofiltration combined with ozone-based processes for the removal of antineoplastic drugs from wastewater effluents. (PubMed, J Environ Manage) - "The applicability of the clean water stream for recharging aquifers used as abstraction sources for drinking water production was supported by a risk assessment approach, regarding the final concentrations of the target pharmaceuticals. Moreover, the toxicity of the nanofiltration retentate, a polluted stream generated from the nanofiltration system, was greatly decreased after the application of the peroxone process, which evidences the positive impact on the environment of implementing a NF + O/HO process."

Journal • Oncology

MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction (clinicaltrials.gov) - P=N/A | N=20 | Recruiting | Sponsor: Brigham and Women's Hospital | Not yet recruiting ➔ Recruiting | Phase classification: P1 ➔ PN/A | Trial completion date: Jan 2024 ➔ Apr 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Erectile Dysfunction

Mechanisms of interfacial catalysis and mass transfer in a flow-through electro-peroxone process. (PubMed, J Hazard Mater) - "To investigate the catalytic mechanism and mass transfer efficiency in the removal of amitriptyline using an electro-peroxide process, a CuFeO-modified carbon cloth cathode was prepared and utilized in a reaction unit. The flow-through cathode design improved the mass transfer of aqueous O and in-situ generated HO, leading to an increased yield of hydroxyl radicals, as well as the contact time and space between hydroxyl radicals and amitriptyline. Ultimately, this resulted in a higher degradation efficiency of the system."

Journal

Treatment of synthetic textile wastewater containing Acid Red 182 by electro-Peroxone process using RSM. (PubMed, J Environ Manage) - "At optimum points, the decolorization performance in predicted and experimental conditions for AR182 were 99 and 98.5%, respectively. The outcomes of this work clearly substantiated that the EP can be successfully utilized for the decolorization of AR182 in textile wastewater."

Journal

"Eroxon, el gel recién aprobado por la @FDA_Drug_Info que estaban esperando los hombres que padecen de #disfuncionerectil esta a la venta SIN RECETA MEDICA. Según la publicidad del producto funciona despues de 10 minutos de aplicarlo, no disponible en Honduras #PeriodismoUNAH" (@elvinmax)

US FDA Grants for Over-the-Counter Marketing Authorization to Futura for Fast-Acting Topical Gel, MED3000, to Treat Erectile Dysfunction (Businesswire) - "Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder....Futura Medical...today announces that the US Food and Drug Administration ('FDA') has granted over the counter sale ('OTC') Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction ('ED') as a De Novo Medical Device....Initial launches commenced under the brand name Eroxon® in March 2023 with further launches planned through 2023 and beyond."

FDA event • Financing • Launch • Erectile Dysfunction • Sexual Disorders